West China Hospital COVID-19 vaccine explained

Type:	vaccine
Target:	SARS-CoV-2
Vaccine Type:	protein
Routes Of Administration:	Intramuscular
Drugbank:	DB16443

West China Hospital COVID-19 vaccine is a COVID-19 vaccine candidate developed by Jiangsu Province Centers for Disease Control and Prevention, West China Hospital and Sichuan University.__TOC__

Clinical trials

In August 2020, WestVac Biopharma started phase I clinical trials with 168 participants in China.^[1]

In November, WestVac Biopharma started phase II clinical trials with 960 participants in China^[2] In February 2021, WestVac Biopharma started phase IIb clinical trials with 4,000 participants in China. Later, WestVac Biopharma is no longer on phase IIb clinical trial.^[3]

In June 2021, WestVac Biopharma started phase III trials with 40,000 participants including Indonesia, Kenya, and the Philippines.

Children and adolescents trials

In August 2021 WestVac Biopharma started phase I/II trials with 600 participants for children and adolescents aged 6-17.

Notes and References

1. Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) . clinicaltrials.gov . 8 February 2021 . United States National Library of Medicine . 20 March 2021 .
2. Web site: A Phase II Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells) . clinicaltrials.gov . United States National Library of Medicine . 20 March 2021 .
3. Web site: Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells) . clinicaltrials.gov . United States National Library of Medicine . 20 March 2021 .